Abstract
This case report describes an adult with high-risk DLBCL (IPI score 4) treated with R-CHOP combined with JK5G and JK21 postbiotics for gut microbiome modulation. The patient achieved significant tumor regression while maintaining stable hematological parameters. Microbial analysis demonstrated enrichment of beneficial genera (Veillonella, Bacteroides, Roseburia), potentially linked to postbiotic intervention. Notably, the regimen exhibited excellent tolerability without leukopenia or severe toxicities, suggesting postbiotics may enhance chemotherapy efficacy through microbiome-immune interactions while mitigating adverse effects. These findings warrant further investigation into postbiotics as adjuvant therapy for optimizing DLBCL treatment outcomes.
| Original language | English |
|---|---|
| Journal | Discover Oncology |
| Volume | 17 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Dec 2025 |
Free Keywords
- Diffuse large B-cell lymphoma
- Gut microbiome
- Immune modulation
- Immunotherapy
- Postbiotics
- R-CHOP chemotherapy
Fingerprint
Dive into the research topics of 'Postbiotic-mediated gut microbiome modulation enhances R-CHOP efficacy in high-risk diffuse large B-cell lymphoma: a case report'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver